Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vanta BioscienceBOM:540729 51 Cyclically Adjusted PB Ratio is 0.55 as of Sep. 07, 2026, which is 10% below its 10-year median of 0.61. GuruFocus rates BOM:540729 with a GF Score™ of 51/100 and a GF Value™ of ₹11.64 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 127 Medical Diagnostics & Research companies, Vanta Bioscience ranks better than 77.17% on this metric.
The historical rank and industry rank for Vanta Bioscience's Cyclically Adjusted PB Ratio or its related term are showing as below:
BOM:540729'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.43 Med: 0.61 Max: 0.71
Current: 0.55
During the past 10 years, Vanta Bioscience's highest Cyclically Adjusted PB Ratio was 0.71. The lowest was 0.43. And the median was 0.61.
BOM:540729's Cyclically Adjusted PB Ratio is ranked better than 77.17% of 127
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.82
vs BOM:540729: 0.55
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Vanta Bioscience's adjusted book value per share data of for the fiscal year that ended in Mar26 was ₹29.774. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ₹35.42 for the trailing ten years ended in Mar26.
Shiller PE for Stocks: The True Measure of Stock Valuation
Vanta Bioscience (BOM:540729) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Vanta Bioscience Cyclically Adjusted PB Ratio Related Terms
Vanta Bioscience Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Vanta Bioscience's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vanta Bioscience Cyclically Adjusted PB Ratio Chart
BOM:540729 vs TMO, DHR, NTRA: Cyclically Adjusted PB Ratio Comparison
For the Diagnostics & Research subindustry, Vanta Bioscience's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vanta Bioscience Cyclically Adjusted PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vanta Bioscience's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Vanta Bioscience's Cyclically Adjusted PB Ratio falls into.
Vanta Bioscience Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Vanta Bioscience's Cyclically Adjusted PB Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 0.55 mean?
Vanta Bioscience (BOM:540729) has a Cyclically Adjusted PB Ratio of 0.55 as of Sep. 07, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Vanta Bioscience and its competitors. This is 10% below median its historical median of 0.61. Over the past decade, Vanta Bioscience's Cyclically Adjusted PB Ratio has ranged from 0.43 to 0.71. According to the industry distribution chart, Vanta Bioscience ranks #29 out of 127 companies in the Medical Diagnostics & Research industry, placing it in the top 22.8%.
Is Vanta Bioscience's Cyclically Adjusted PB Ratio too high?
Vanta Bioscience's current Cyclically Adjusted PB Ratio of 0.55 is 10% below median its 10-year median of 0.61. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 0.71. The Medical Diagnostics & Research industry median Cyclically Adjusted PB Ratio is 1.82. Vanta Bioscience's value of 0.55 is 69.8% below this industry median. Based on the distribution chart, Vanta Bioscience ranks #29 out of 127 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Vanta Bioscience has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vanta Bioscience's Cyclically Adjusted PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vanta Bioscience ranks #29 out of 127 companies for Cyclically Adjusted PB Ratio. This places Vanta Bioscience in the top 23% of its industry — outperforming the majority of peers. The industry median Cyclically Adjusted PB Ratio is 1.82. Vanta Bioscience's value of 0.55 is 69.8% below this benchmark. Historically, Vanta Bioscience's own Cyclically Adjusted PB Ratio has ranged from 0.43 to 0.71 over the past decade. While the company's 10-year median is 0.61 vs. the industry median of 1.82, Vanta Bioscience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Medical Diagnostics & Research company?
The median Cyclically Adjusted PB Ratio among Medical Diagnostics & Research companies is 1.82, based on 127 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vanta Bioscience's current Cyclically Adjusted PB Ratio of 0.55 is 69.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Vanta Bioscience and its competitors. For the Medical Diagnostics & Research industry, the median Cyclically Adjusted PB Ratio is 1.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vanta Bioscience's current Cyclically Adjusted PB Ratio is 0.55, which is 10% below median its own 10-year median of 0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanta Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Vanta Bioscience (BOM:540729) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹11.64, compared to a current price of ₹19.64 — trading 68.7% above its estimated fair value. The current Cyclically Adjusted PB Ratio is 0.55, which is 10% below median its 10-year median of 0.61 and 69.8% below the Medical Diagnostics & Research industry median of 1.82. Vanta Bioscience's overall GF Score™ is 51/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Vanta Bioscience (BOM:540729), the current Cyclically Adjusted PB Ratio is 0.55 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vanta Bioscience (BOM:540729) Overvalued in 2026?
Based on GuruFocus' analysis, Vanta Bioscience stock appears to be overvalued.
The current stock price of ₹19.64 is trading 68.7% above its estimated GF Value™ of ₹11.64.
GuruFocus considers Vanta Bioscience to be Significantly Overvalued.
Key valuation signals for BOM:540729:
Cyclically Adjusted PB Ratio: 0.55 (10% below median its 10-year median of 0.61)
GF Value™: ₹11.64 vs. price of ₹19.64 (68.7% above fair value)
Industry Position: 69.8% below the Medical Diagnostics & Research median (#29 of 127)
No single metric tells the full story. See the BOM:540729 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vanta Bioscience Ltd is a full-service preclinical contract research organization based in Chennai, India, providing preclinical safety assessment services for the pharmaceutical, medical devices, nutraceuticals, biotech, agrochemicals, cosmetics, chemical, and feed additive industries. Established as a center of excellence in GLP-compliant toxicology and safety assessment, the company supports clients through toxicology studies, batch release tests, biocompatibility evaluations, agro-chemical and chemical safety assessments, and diet formulation services. It also offers testing and contract research services in clinical and pre-clinical research, biopharma studies, analytical testing, and environmental assessments.
51GF Score
Get the complete analysis for BOM:540729
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540729 has been successfully added to your 
